Bayer seeks to reclaim losses from Chiron on Rapidpoint 400
This article was originally published in Clinica
Bayer is claiming that US biotechnology company Chiron failed to disclose technical faults associated with the Rapidpoint 400 blood gas analyser when Bayer acquired Chiron's diagnostics arm in 1998 (see Clinica No 826, p 1). Bayer recalled the product in early 1999, press reports state, and now, having relaunched the product, has filed suit in a Delaware district court (civil case 02-80). The claim for damages runs into several million dollars. The Wall Street Journal suggests a claim figure of $13.5 million.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.